| Literature DB >> 33285423 |
Kristijan Skok1, Klaus Vander2, Lisa Setaffy3, Harald H Kessler4, Stephan Aberle5, Ute Bargfrieder6, Michael Trauner7, Sigurd F Lax8.
Abstract
Autopsies on COVID-19 have provided deep insights into a novel disease with unpredictable and potentially fatal outcome. A standardized autopsy procedure preferably with an in-situ technique and systematic tissue processing is important. Strict safety measures include personal protective equipment with a standardized protocol for dressing and undressing, usage of FFP-3 masks and minimization of aerosol production. The use of an airborne infection isolation (AIIR) room is preferred. Viral RNA analysis using swabs from throat, both lungs and other organs provides information on cross-organ viral dynamics. To correctly determine the full extent of pathological organ changes an adequate processing procedure is of the utmost importance. Systematic dissection and processing of the lungs revealed pulmonary infarction caused by thrombosis and thromboembolism and bacterial bronchopneumonia as the most frequent cause of death. Fungal pneumonia (aspergillus) was found in one case. The quality of the tissue was sufficient for histopathological and immunohistochemistry analyses in all cases. Viral RNA from throat or lung swabs was detectable post mortem in 89 % of the cases and could also be detected from paraffin-embedded tissue by real-time PCR. Complete COVID-19 autopsies including extensive histopathological studies and viral RNA analysis require approximately three times more human and technical resources and time compared to standard non-COVID autopsies. Autopsies on COVID-19 are feasible, present a manageable risk, while following a strict protocol, and provide novel insights into disease pathogenesis and the clinician with important feedback.Entities:
Keywords: Autopsy; COVID-19; Cause of death; Pneumonia; Post mortem; SARS-CoV-2
Year: 2020 PMID: 33285423 PMCID: PMC7699304 DOI: 10.1016/j.prp.2020.153305
Source DB: PubMed Journal: Pathol Res Pract ISSN: 0344-0338 Impact factor: 3.250
Fig. 1Autopsy equipment (A) and room (B).
Personal protection and hygiene for COVID-19 autopsies in our department.
| Universal personal protective equipment (PPE) | |
|---|---|
Surgical scrubs Surgical cap FFP3 mask Face shield Waterproof surgical gown Waterproof surgical sleeve protectors Plastic apron OR shoes Protective cut-resistant polyethylene gloves (proFood™ Knitted Spectra®) Single use disposable latex gloves (2 pairs) |
According to our internal hygiene standard for the treatment and care of COVID-19 patients and WHO (www.who.int).
Fig. 2Summarized COVID-19 autopsy checklist.
Fig. 4The lungs were sliced after fixation in total (A) and systematically examined grossly and by multiple histological samples. On the cut surface pulmonary arteries occluded by thrombotic material are visible (B).
Fig. 5Large tissue samples (A) from the lungs were blocked for giant sections (B) allowing better demonstration of the pathological changes.
Clinicopathological and viral RNA analysis of the 28 autopsy cases.
| Patients' Characteristics | N = 28 |
|---|---|
| Age | 80.7 (57−96) |
| Sex | M:F = 16:12 |
| Diabetes mellitus | 8 (29 %) |
| Obesity | 4 (14 %) |
| Arterial hypertension | 23 (82 %) |
| COPD | 5 (18 %) |
| Cerebrovascular diseases | 8 (29 %) |
| Dementia | 11 (39 %) |
| Previous or current malignancy | 7 (25 %) |
| Diffuse alveolar damage | 28 (100 %) |
| Severe COPD | 9 (32 %) |
| Pulmonary artery thrombosis | 28 (100 %) |
| Pulmonary thromboembolism | 6 (21 %) |
| Pulmonary Infarction | 21 (75 %) |
| Bronchopneumonia | 16* (57 %) |
| Pulmonary fibrosis | 20 (71 %) |
| Arteriosclerosis (moderate or severe) | 28 (96 %) |
| Coronary arteriosclerosis (moderate or severe) | 24 (86 %) |
| Left ventricular hypertrophy | 26 (93 %) |
| Myocardial fibrosis | 14 (50 %) |
| Cardiac amyloidosis | 4 (14 %) |
| Heart weight (g) | 430 (210−700) |
| Ischemic bowel changes | 6** (24 %) |
| Acute tubular injury of the kidney | 28 (100 %) |
| Bronchopneumonia (with infarction or hypostasis) | 14 (50 %) |
| Pulmonary infarction (by thrombosis and/or thromboembolism) | 9 (32 %) |
| ARDS (including pulmonary artery thrombosis) | 4 (14 %) |
| Brain stem infarction | 1 (4%) |
| Pharynx | 21 (75 %) |
| Right lung | 22† (81 %) |
| Left lung | 21 (75 %) |
| Intestine | 7† (37 %) |
| Brain (including liquor) | 1† (10 %) |
Legend: * fungal pneumonia in 1 case; **not assessed in 3 cases; †not all cases were analyzed.
Fig. 6Major causes of death in COVID-19: Thromboembolism in large pulmonary arteries (A), thrombosis of asmall pulmonary artery (“microthrombosis”) associated with diffuse alveolar damage (B), lung infarction (C) and bacterial bronchopneumonia (D). HE, original magnification 10x (A, C), 40x (B), 100x (D).
Fig. 7Preserved quality of tissue for histopathological and immunohistochemical analysis despite autolysis: Lung tissue with proliferative phase of diffuse alveolar damage (A) with TTF1 immunoreactivity of alveocytes (B) showing extensive macrophage reaction by CD68 (C) and mild lymphocytic infiltrate by CD3 (D) immunoreactivity. SARS-CoV-2 RNA could be detected from the same tissue block by RT-PCR. HE (A), DAB (B-D). Original magnification 100×.